Trial Profile
An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (150/25 mg and 300/25 mg) in Comparison With HCTZ 25 mg in Patients With Essential Hypertension Not Adequately Responsive to HCTZ 25 mg Monotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Aliskiren/hydrochlorothiazide (Primary) ; Hydrochlorothiazide
- Indications Essential hypertension; Hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 19 Jun 2008 Primary efficacy endpoint results presented at ESH-ISH in June 2008
- 15 May 2008 Results were presented at the 23rd annual scientific meeting of the American Society of Hypertension (ASH).
- 15 May 2008 Status changed from in progress to completed based on information from a Novartis media release stating that results were presented at ASH.